NCT06467565View on ClinicalTrials.gov

NALIRIFOX as Induction Therapy in LAPC

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Liposomal irinotecan

NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.

Trial Locations (1)

025

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER